| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Nadunolimab
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Nadunolimab (anti-IL-1 RAcP)
CAS:2171061-85-9
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10702
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Nidanilimab
CAS:2171061-85-9
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Nadunolimab
CAS:2171061-85-9
Purity:95% Package:1mg;1g;100g
|
|
| | Nidanilimab Basic information |
| Product Name: | Nidanilimab | | Synonyms: | Nidanilimab;Research Grade Nadunolimab(DHJ63401);Nadunolimab (anti-IL-1 RAcP);CAN04;Research Grade Nadunolimab;Nadunolimab;Nidanilimab (Nadunolimab) | | CAS: | 2171061-85-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Nidanilimab Structure]() |
| | Nidanilimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Nidanilimab Usage And Synthesis |
| Uses | Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2]. | | in vivo | Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies[1]. | Animal Model: | Nude C57Bl/6 mice with LU2503 NSCLC PDX model[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy. |
| | IC 50 | IL-1α; IL-1β | | References | [1] Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
[2] Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. DOI:10.1007/s00262-022-03277-3 |
| | Nidanilimab Preparation Products And Raw materials |
|